OBJECTIVES: To assess the efficacy of bilateral subthalamic nucleus (STN) deep brain stimulation (DBS) in patients with advanced Parkinson's disease previously reliant on apomorphine as their main antiparkinsonian medication. METHODS: Seven patients with motor fluctuations despite optimal medical treatment given as predominantly apomorphine infusion (n=6), or intermittent apomorphine injections (n=1) underwent bilateral STN DBS using frameless stereotactic surgery. Standard assessments of parkinsonism and motor fluctuations, using Unified Parkinson's Disease Rating Scale (UPDRS) were performed before and six months after surgery. Assessments were performed both on and off medication, and postoperative with the stimulators switched on and off. RESULTS: Bilateral STN DBS improved motor scores (UPDRS III) by 61% when off medication (p<0.05). Clinical fluctuations (UPDRS IV items 36-39) were reduced by 46.2% (p<0.05). Total daily apomorphine dose was reduced by 68.9% (p<0.05) and apomorphine infusion via a pump was no longer required in four patients. There were no operative complications. Two patients required treatment for hallucinations postoperatively but there was no significant change in mini-mental state examination. CONCLUSIONS: In patients with advanced Parkinson's disease, previously reliant on apomorphine, bilateral STN DBS is an effective treatment to reduce motor fluctuations and enable a reduction in apomorphine use.
OBJECTIVES: To assess the efficacy of bilateral subthalamic nucleus (STN) deep brain stimulation (DBS) in patients with advanced Parkinson's disease previously reliant on apomorphine as their main antiparkinsonian medication. METHODS: Seven patients with motor fluctuations despite optimal medical treatment given as predominantly apomorphine infusion (n=6), or intermittent apomorphine injections (n=1) underwent bilateral STN DBS using frameless stereotactic surgery. Standard assessments of parkinsonism and motor fluctuations, using Unified Parkinson's Disease Rating Scale (UPDRS) were performed before and six months after surgery. Assessments were performed both on and off medication, and postoperative with the stimulators switched on and off. RESULTS: Bilateral STN DBS improved motor scores (UPDRS III) by 61% when off medication (p<0.05). Clinical fluctuations (UPDRS IV items 36-39) were reduced by 46.2% (p<0.05). Total daily apomorphine dose was reduced by 68.9% (p<0.05) and apomorphine infusion via a pump was no longer required in four patients. There were no operative complications. Two patients required treatment for hallucinations postoperatively but there was no significant change in mini-mental state examination. CONCLUSIONS: In patients with advanced Parkinson's disease, previously reliant on apomorphine, bilateral STN DBS is an effective treatment to reduce motor fluctuations and enable a reduction in apomorphine use.
Authors: J A Obeso; M C Rodriguez-Oroz; M Rodriguez; R Macias; L Alvarez; J Guridi; J Vitek; M R DeLong Journal: Neurology Date: 2000 Impact factor: 9.910
Authors: A M Lozano; A E Lang; N Galvez-Jimenez; J Miyasaki; J Duff; W D Hutchinson; J O Dostrovsky Journal: Lancet Date: 1995-11-25 Impact factor: 79.321
Authors: R Carron; V Fraix; C Maineri; E Seigneuret; B Piallat; P Krack; P Pollak; A L Benabid; Stéphan Chabardès Journal: J Neural Transm (Vienna) Date: 2010-12-29 Impact factor: 3.575
Authors: Trent J Bradberry; Leonard Verhagen Metman; José L Contreras-Vidal; Pepijn van den Munckhof; Lara A Hosey; Jennifer L W Thompson; Geralyn M Schulz; Fredrick Lenz; Rajesh Pahwa; Kelly E Lyons; Allen R Braun Journal: Brain Stimul Date: 2011-10-05 Impact factor: 8.955
Authors: Swen Hesse; Karl Strecker; Dirk Winkler; Julia Luthardt; Christoph Scherfler; Annegret Reupert; Christian Oehlwein; Henryk Barthel; Jens-Peter Schneider; Florian Wegner; Philipp Meyer; Jürgen Meixensberger; Osama Sabri; Johannes Schwarz Journal: J Neurol Date: 2008-05-02 Impact factor: 4.849
Authors: Hilary L Tyne; Jan Parsons; Ann Sinnott; Susan H Fox; Nicholas A Fletcher; Malcolm J Steiger Journal: J Neurol Date: 2004-11 Impact factor: 4.849
Authors: B Ford; L Winfield; S L Pullman; S J Frucht; Y Du; P Greene; J H Cheringal; Q Yu; L J Cote; S Fahn; G M McKhann; R R Goodman Journal: J Neurol Neurosurg Psychiatry Date: 2004-09 Impact factor: 10.154